Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer

NCT00373256 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00373256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00373256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
August 31, 2011
Enrollment
488 (actual)
Sites
250

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms